Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography

Chest

Volumn 114, Issue 3, 1998, Pages 713-722

  Bénard, François ^a   Sterman, Daniel ^a   Smith, Robin J ^a   Kaiser, Larry R ^a   Albelda, Steven M ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

FDG; Malignant mesothelioma; Metabolic imaging; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG BIOPSY; LYMPH NODE METASTASIS; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORACOSCOPY;

EID: 0031695852     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.114.3.713     Document Type: Article

References (48)

1. McLoud T. Conventional radiography in the diagnosis of asbestos-related disease. Radiol Clin North Am 1992; 30: 1177-1189
2. Muller N. Imaging of the pleura. Radiology 1993; 186:297-309
3. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 1990; 154:487-492
4. Falaschi F, Battolla L, Mascalchi M, et al. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. AJR Am J Roentgenol 1996; 166:963-968
5. Teirstein A, Chahinian C, Goldsmith S, et al. Gallium scanning in differentiation malignant from benign asbestos-related pleural disease. Am J Ind Med 1986; 9:487-494
6. Rigo P, Paulus P, Kaschten B, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23:1641-1674
7. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992; 184:441-444
8. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490
9. Coleman R. Multicenter prospective study of FDG-PET in the evaluation of indeterminate solitary pulmonary nodules (SPN). J Nucl Med 1995; 36:94P
10. Karp JS, Muehllehner G. Standards for performance measurements of PET scanners: evaluation with the UGM PENN-PET 240H scanner. Med Prog Technol 1991; 17: 173-187
11. Smith R, Karp J. Post-injection transmission scans in a PET camera operating without septa with simultaneous measurement of emission activity contamination. IEEE Trans Nucl Sci 1996; 43:2207-2212
12. Smith R, Karp J, Muehllehner G, et al. Singles transmission scans performed post-injection for quantitative whole body PET imaging. IEEE Trans Nucl Sci 1997; 44:1329-1335
13. Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35:1771-1776
14. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36:1836-1839
15. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373S-376S
16. Nicholson W, Perkel G, Selikoff I. Occupational exposure to asbestos: population at risk and projected mortality - 1980-2030. Am J Ind Med 1982; 3:259-311
17. Begin R, Gauthier J, Desmeules M, et al. Work-related mesothelioma in Québec, 1967-1990. Am J Ind Med 1992; 22:531-542
18. Connelly R, Spirtas R, Myers M, et al. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987; 78:1053-1060
19. Pisani R, Colby T, Williams D. Malignant mesothelioma of the pleura. Mayo Clin Proc 1988; 63:1234-1244
20. Butchart EG, Ashcroft T, Barnsley WC, et al. The role of surgery in diffuse malignant mesothelioma of the pleura. Semin Oncol 1981; 8:321-328
21. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 1995; 108: 1122-1128
22. Roberts GH. Diffuse pleural mesothelioma: a clinical and pathological study. Br J Dis Chest 1970; 64:201-211
23. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest 1995; 107:3455-3505
24. Rusch V, Godwin J, Shuman W. The role of computed tomography scanning in the initial assessment and follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1988; 96:171-177
25. Heelan R. CT and MR imaging in the evaluation of pleural masses. Chest Surg Clin North Am 1994; 4:431-451
26. Boutin C, Loddenkemper R, Astoul P. Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine. Tuber Lung Dis 1993; 74:225-239
27. Metintas M, Ozdemir N, Isiksoy S, et al. CT-guided pleural biopsy in the diagnosis of malignant mesothelioma. J Comput Assist Tomogr 1995; 19:370-374
28. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients: II. Prognosis and staging. Cancer 1993; 72:394-404
29. Kaiser L, Bavaria J. Complications of thoracoscopy. Ann Thorac Surg 1993; 56:431-451
30. Ryan C, Rodgers R, Unni K, et al. The outcome of patients with pleural effusion of indeterminate cause at thoracotomy. Mayo Clin Proc 1981; 56:145-149
31. Lowe V, Patz E, Harris L, et al. FDG-PET evaluation of pleural abnormalities [abstract]. J Nucl Med 1994; 35:228P
32. Bury T, Paulus P, Weber T, et al. Potential interest of pleural diseases evaluation with FDG-PET imaging: preliminary report [abstract]. Eur J Nucl Med 1996; 23:1186
33. Kubota R, Kubota K, Yamada S, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980
34. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36:1301-1306
35. Larson S. Cancer or inflammation? a holy grail for nuclear medicine. J Nucl Med 1994; 35:1653-1655
36. Lewis P, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649
37. Meyer M, Gast T, Raja S, et al. Increased F-18-FDG accumulation in acute fracture. Clin Nucl Med 1994; 35: 1647-1649
38. Tichler M, Fagam J. Response to trauma of protein, aminacid, and carbohydrate metabolism in injured and uninjured rat skeletal muscles. Metabolism 1983; 32:853-868
39. Tahara T, Ichiya Y, Kuwabara Y, et al. High fluorodeoxyglucose uptake in abdominal abcesses: a PET study. J Comput Assist Tomog 1989; 13:829-831
40. Sasaki M, Ichiya Y, Kuwabara Y, et al. Ring-like uptake of FDG in brain abcess: a PET study. J Comput Assist Tomog 1990; 14:486-487
41. Patz E, Shaffer K, Piwnica-Worms D, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 1992; 159:961-966
42. Chin R Jr, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995; 152:2090-2096
43. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-377
44. Bury T, Dowlati A, Paulus P, et al. Staging of non-small cell lung cancer by whole-body FDG-PET [abstract]. Eur J Nucl Med 1996; 23:204-206
45. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60:1573-1581; discussion 1581-1582
46. Buchpiguel C, Tse K, Alavi A, et al. Use of quantitative FDG-PET whole-body imaging in staging lung cancer: a comparison with CT [abstract]. J Nucl Med 1995; 36:196P
47. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178:705-713
48. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182:319-323